Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in

Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023

Current Issue

01 Jan 2026 (Vol. 93 Issue 1) Table of Contents
Cleveland Clinic Journal of Medicine: 93 (1)

Issue highlights

  • Update on antiobesity pharmacotherapy in adults: Current and emerging options
  • Vaccine hesitancy: Where are we heading?
  • Do corticosteroids prevent reactions to infusions of contrast, monoclonal antibodies, or chemotherapy?

Summaries from Kidney Week 2025

Summaries from ACR Convergence 2025

Featured Articles

  • Pseudoxanthoma elasticum
    January 02, 2026
  • Atrial fibrillation in patients with obesity: How can we optimize management?
    January 02, 2026
  • More on the myths and perceived magic of corticosteroids
    January 02, 2026
  • How can I select the right thyroid hormone formulation for my patient with hypothyroidism?
    December 01, 2025
  • Trident sign in osmotic demyelination syndrome
    December 01, 2025
  • Diabetes: Putting off until tomorrow what could happen today can be good
    December 01, 2025
  • Multiple scabietic nodules on the scrotum in a patient living with HIV infection
    November 03, 2025
  • Teprotumumab for thyroid eye disease: A reality check
    November 03, 2025
  • Lipoprotein(a) in clinical practice: What clinicians need to know
    November 03, 2025
  • Nearly a century of using glucocorticoids in patients with active infection
    October 01, 2025
  • MDA5 dermatomyositis: Unveiling a potentially life-threatening disease
    October 01, 2025
  • What is the role of cystatin C in estimating glomerular filtration rate and guiding medication...
    September 02, 2025
  • An overview of over-the-counter contraceptives: Spotlight on daily oral norgestrel
    September 02, 2025
  • Acute respiratory distress syndrome: Why a definition matters
    September 02, 2025
  • Does my patient need testing for PFAS ‘forever chemicals’?
    August 01, 2025
  • Newer diabetes drugs: Surprising shared benefits and unique side effects
    August 01, 2025
  • The overlooked and undertreated perils of premature ovarian insufficiency
    August 01, 2025
  • Insights from the LAAOS III trial of left atrial appendage occlusion to prevent stroke in atrial...
    July 01, 2025
  • Breast cancer risk and screening for transgender and gender-diverse individuals
    July 01, 2025
  • Immunotherapy meets William Shakespeare
    July 01, 2025

Latest Articles

  • You have access
    Atrial fibrillation in patients with obesity: How can we optimize management?
    Asim Kichloo, MD, Ivan Magallanes Marrufo, MPH and Suhaib Andrabi, MD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 17-20; DOI: https://doi.org/10.3949/ccjm.93a.25032

    Heart rate and rhythm control therapies often must be adjusted when treating patients with obesity, while other measures can reduce the onset or recurrence of atrial fibrillation.

  • You have access
    Do corticosteroids prevent reactions to infusions of contrast, monoclonal antibodies, or chemotherapy?
    CME article
    Dylan T. Timberlake, MD, Sushmitha Boppana, MD and James Fernandez, MD, PhD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 47-53; DOI: https://doi.org/10.3949/ccjm.93a.25026

    The data and recommendations about corticosteroid pretreatment vary by medication class and the individual medication, necessitating a medication- and patient-specific approach.

  • You have access
    Pseudoxanthoma elasticum
    Kathleen Kramer, MD, Sama Alazawi, DO and Rudy Schmiedecke, MD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 13-14; DOI: https://doi.org/10.3949/ccjm.93a.25021

    The patient presented for evaluation of yellowish plaques on her neck that had been present since childhood.

  • You have access
    More on the myths and perceived magic of corticosteroids
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 6-7; DOI: https://doi.org/10.3949/ccjm.93b.01026

    It is widely accepted that corticosteroids can partially prevent infusion reactions to intravenous diagnostic and therapeutic agents, but evidence to support this concept is scant.

  • You have access
    Update on antiobesity pharmacotherapy in adults: Current and emerging options
    Farah Ziyadeh, MD, Sara Saliba, MD, RD, Dania Salih Bacha, MD, Yael Mauer, MD, MPH, Marcio L. Griebeler, MD, DABOM and Bartolome Burguera, MD, PhD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 36-46; DOI: https://doi.org/10.3949/ccjm.93a.24112

    The authors review antiobesity medications that are currently available or under investigation and discuss how to personalize obesity treatment.

  • A young woman with Kallmann syndrome and acute neurologic symptoms
    You have access
    A young woman with Kallmann syndrome and acute neurologic symptoms
    Jumaina F. Ali, MBChB, Adhithya Sankar, MBChB, PhD, Mohammed S. O. Ahmed, MBBS, MSc, Mark Woodward, BSc (Hons), MBChB and Akheel A. Syed, MBBS, PhD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 29-34; DOI: https://doi.org/10.3949/ccjm.93a.25010

    Diagnoses considered on initial presentation included conditions that present with stroke-like symptoms such as seizure, hemiplegic migraine, transient ischemic attack, and brain tumor.

  • You have access
    Vaccine hesitancy: Where are we heading?
    Sherif Beniameen Mossad, MD
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 21-26; DOI: https://doi.org/10.3949/ccjm.93a.25104

    Vaccination recently was hailed as one of the top 10 public health achievements of the 20th century; now, the World Health Organization lists vaccine hesitancy among the top 10 threats to global health.

  • You have access
    Multicentric reticulohistiocytosis
    Atul Khasnis, MD, MS and Joseph M. Dyer, DO
    Cleveland Clinic Journal of Medicine January 2026, 93 (1) 9-11; DOI: https://doi.org/10.3949/ccjm.93a.24124

    A 58-year-old man presented with a 2-month history of joint pain and swelling and a rash.

  • You have access
    Corticosteroids in severe community-acquired pneumonia
    Enmanuel A. Leiva-Murillo, MD and Rosanel Amaro-Rodríguez, MD, PhD
    Cleveland Clinic Journal of Medicine December 2025, 92 (12) 723-724; DOI: https://doi.org/10.3949/ccjm.92c.12005
  • You have access
    Should I consider low-dose rivaroxaban (2.5 mg) for my patient with peripheral artery disease?
    Pranay Marlecha, MD, Deborah Hornacek, MD and Pulkit Chaudhury, MD, MS
    Cleveland Clinic Journal of Medicine December 2025, 92 (12) 742-744; DOI: https://doi.org/10.3949/ccjm.92a.25065

    For patients with high ischemic risk, rivaroxaban 2.5 mg twice daily with aspirin 81 or 100 mg daily is a proven strategy to reduce major cardiovascular and limb events.

View more latest articles
  • Editor's Picks
  • Most Cited
  • Most Read
Loading
A young woman with Kallmann syndrome and acute neurologic symptoms
Multicentric reticulohistiocytosis
Finding the cause of severe hypokalemia: A 4-step approach
How should I incorporate emergency contraception counseling into my practice?
Acute transient phlebitis after a morphine infusion
Rethinking recovery in heart failure: Beyond improvement in left ventricular ejection fraction
Failure to thrive in hospitalized older adults: More than a ‘social admission’
What is the optimal time for bone density screening in patients with premature ovarian insufficiency?
No surprise, all inflammation is not created equal as it relates to cardiovascular disease
Benign migratory glossitis
Flexibility is warranted in applying prescribing guidelines
How can I help my pregnant patients quit using tobacco?
Half-moccasin distribution of acute tinea pedis
Cerebrovascular complications in infective endocarditis: Challenges and considerations in management
Evolving paradigms in hypertension management: Fixed-dose single-pill combinations and future therapies
Refractory granuloma annulare

Cleveland Clinic Journal of Medicine, published by Cleveland Clinic, provides busy clinicians with practical information to promote better patient care.

Back to top

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2026 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire